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Neisseria gonorrhoeae antimicrobial resistance (AMR) 
is a globally recognized health threat; new strategies are 
needed to enhance AMR surveillance. The Northern Terri-
tory of Australia is unique in that 2 different first-line thera-
pies, based primarily on geographic location, are used for 
gonorrhea treatment. We tested 1,629 N. gonorrhoeae 
nucleic acid amplification test–positive clinical samples, 
collected from regions where ceftriaxone plus azithromycin 
or amoxicillin plus azithromycin are recommended first-line 
treatments, by using 8 N. gonorrhoeae AMR PCR assays. 
We compared results with those from routine culture-based 
surveillance data. PCR data confirmed an absence of ceftri-
axone resistance and a low level of azithromycin resistance 
(0.2%), and that penicillin resistance was <5% in amoxicillin 
plus azithromycin regions. Rates of ciprofloxacin resistance 
and penicillinase-producing N. gonorrhoeae were lower 
when molecular methods were used. Molecular methods 
to detect N. gonorrhoeae AMR can increase the evidence 
base for treatment guidelines, particularly in settings where 
culture-based surveillance is limited.
Resistance to antimicrobial drugs (termed antimicro-bial resistance [AMR]) in Neisseria gonorrhoeae is 
recognized as a public health problem of global impor-
tance (1,2). The overall magnitude of AMR in N. gonor-
rhoeae is largely unknown in many regions because of 
substantial gaps in global AMR surveillance (3). Ceftri-
axone, a third-generation extended-spectrum cephalospo-
rin used widely for treatment, is considered to be the last 
fully effective option currently recommended. However, 
its durability is not assured; the proportion of gonococ-
cal strains with elevated ceftriaxone MIC values is in-
creasing steadily, and 4 documented cases of resistance 
to ceftriaxone have been noted, in Japan, France, Spain, 
and Australia (4–6). A dual therapy treatment regimen of 
ceftriaxone plus azithromycin is now the recommended 
standard of care in many countries and was implemented 
in an effort to stem further development of ceftriaxone 
resistance (7); however, failure of this dual therapy has 
also been reported (8).
Surveillance of N. gonorrhoeae antimicrobial drug sen-
sitivity is a key component of all strategies to manage the 
emergence of resistance; gonorrhea treatment guidelines 
are currently formulated under the principle that an anti-
microbial drug should be rejected for clinical use in a par-
ticular population once a threshold of 5% resistant isolates 
is breached (1). However, although gonorrhea diagnosis is 
now widely based on nucleic acid methods, antimicrobial 
drug sensitivity remains dependent on culture-based meth-
ods, which are highly specific but difficult to implement in 
many settings where gonorrhea is prevalent. The World 
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 Resistance Surveillance for N. gonorrhoeae
Health Organization (WHO) and Centers for Disease Con-
trol and Prevention (CDC), in their action plans to control 
the spread of drug-resistant N. gonorrhoeae, have called for 
the development of molecular assays (1,2). We have pre-
viously reviewed the potential for real-time PCR assays to 
achieve these goals (3) and, through the Gonorrhoea Re-
sistance Assessment by Nucleic Acid Detection (GRAND) 
study, developed and validated a range of PCR methods to 
detect resistance mutations for azithromycin, ciprofloxacin, 
and penicillin. We have also developed a high-throughput 
single-nucleotide polymorphism–based typing method for 
multilocus sequence type (MLST) investigations (9).
In Australia, gonorrhea is concentrated primarily in 
men who have sex with men living predominantly in urban 
and regional areas and in Aboriginal heterosexual persons 
living in remote areas of central and northern Australia. 
Dual therapy comprising ceftriaxone (500 mg intramus-
cular injection) and oral azithromycin (1 g) (known as 
CAZ) is used as the standard first-line treatment in urban 
areas. However, in remote areas of the Northern Territory 
(Figure 1) and Western Australia, where rates of infection 
among Aboriginal populations are high and AMR is low, 
first-line treatment is oral amoxicillin 3 g, probenecid 1 
g, and azithromycin 1 g (locally known as a ZAP pack), a 
treatment strategy that has the benefits of oral administra-
tion and avoidance of the unnecessary use of ceftriaxone.
In remote parts of Australia, including much of the 
ZAP pack region, transport distances and climate pose 
limits on the viability of samples for culture. Also, even 
though all clinicians diagnosing or suspecting gonor-
rhea in Australia are encouraged to send a suitable swab 
specimen for AMR testing by culture, changes to test 
reimbursement schemes have tended to favor use of 
nucleic acid amplification test (NAAT) over culture 
for gonorrhea diagnosis. For these combined reasons, 
relatively few isolates are available for AMR testing 
from these areas (10). Our PCR-based method (11,12) 
for direct detection of penicillinase-producing N. gon-
orrhoeae (PPNG) is now routinely used to help inform 
treatment guidelines in Western Australia (13) and the 
Northern Territory. We report on a study that we have 
undertaken in the Northern Territory to comprehensive-
ly examine the utility of nucleic acid methods to assess 
AMR against a broad range of antimicrobial drugs, and 
the potential role of these methods in setting treatment 
guidelines. The study was approved by the Human Re-
search Ethics Committee (HREC) of Northern Territory 
Department of Health and Menzies School of Health, 
the Central Australian HREC, the South Eastern Sydney 
Local Health District HREC, the Queensland Children’s 
Health Services District HREC, and the University of 
Queensland HREC.
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Figure 1. Collection areas 
for Neisseria gonorrhoeae 
samples within the Northern 
Territory of Australia, 2014. 
A) Heat map showing the 
local government areas from 
which the 1,629 nucleic acid 
amplification test–positive 
clinical samples were 
collected. B) Location of 
the Northern Territory within 
Australia. C) Location of 
the CAZ and ZAP regions 
within the Northern Territory. 
CAZ, ceftriaxone via 
intramuscular injection and 
oral azithromycin;  
ZAP, azithromycin, 
amoxicillin, probenecid. 
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Material and Methods
N. gonorrhoeae NAAT-Positive Clinical Samples
For this study, we examined 1,629 N. gonorrhoeae NAAT-
positive clinical samples collected from patients in the 
Northern Territory (441 from CAZ regions and 1,188 from 
ZAP regions; Figure 1) during 2014; these samples repre-
sented 93.6% of the total 1,740 notifications of gonorrhea 
in this region for this year. The samples comprised 21 rec-
tal, 45 pharyngeal, 413 vaginal/cervical, 97 male urethral, 
and 1 ocular specimen, as well as 1,012 urine samples (590 
from men, 418 from women, and 4 from persons whose sex 
was not specified), 21 joint fluid samples, and 19 samples 
for which the site was not recorded on the request form. 
Samples were taken from 756 (46.4%) men, 861 (52.9%) 
women, and 12 (0.7%) persons for whom sex was not speci-
fied; median age was 24 years. The specimens were provid-
ed by the 2 laboratories in the Northern Territory that diag-
nose gonorrhea: Royal Darwin Hospital Pathology, which 
used Siemens Versant Chlamydia trachomatis/N. gonor-
rhoeae (CT/NG) assays (Siemens, Bayswater, Victoria, 
Australia), and Western Diagnostic Pathology, which used 
the Aptima Combo 2 test for CT/NG (Hologic, Bedford, 
MA, USA) (additional information in online Technical Ap-
pendix Table, https://wwwnc.cdc.gov/EID/article/23/9/17-
0427-Techapp1.pdf). 
PCR Methods 
We used 8 PCR methods for AMR testing (Table 1): assays 
to detect PPNG (PPNG-PCR) (11); the mosaic penicillin 
binding protein 2 (PBP2) associated with resistance to the 
extended-spectrum cephalosporins (mosaicPBP2-PCR); 
the A8806 strain of ceftriaxone-resistant gonorrhea pre-
viously detected in Australia (A8806-PCR assay) (6); the 
GyrA S91F alteration that is highly predictive of resistance 
to ciprofloxacin (GyrA91-PCR) (14,15); 2 mutations on 
the 23S rRNA genes conferring resistance to azithromy-
cin (2611-PCR and 2059-PCR) (16); wild-type PorB se-
quences (G101/A102 and PorB1a) that we have shown are 
predictive of penicillin susceptibility, and mutant PorB 
sequences (G101K/A102D, G101K/A102N and G101K/
A102G) that are associated with but not predictive of peni-
cillin resistance (PorB-PCR) (17); and a wild-type mtrR ef-
flux pump promoter (i.e., lacking the A-deletion) shown to 
be associated with susceptibility to β lactam antimicrobial 
drugs (mtrR A-deletion-PCR) (online Technical Appendix; 
18). We considered samples uncharacterized by a method 
if they did not provide a result (e.g., of mutant or wild type) 
in the respective PCR. For mosaicPBP2-PCR and A8806-
PCR, we pooled samples (10 samples/pool) for testing; we 
then tested samples from any pools returning positive re-
sults individually. For all other PCR methods, we tested 
samples individually (online Technical Appendix). 
MLST
We genotyped the first 717 samples (collected during Janu-
ary–May 2014) using a previously described iPLEX14SNP 
method (9). The iPLEX14SNP targets 14 informative sin-
gle-nucleotide polymorphisms on gonococcal housekeep-
ing genes and provides a high-throughput means of con-
ducting N. gonorrhoeae MLST. We further used these data 
to clarify the potential movement of strains between the 
CAZ and ZAP zones, irrespective of their AMR profiles.
Multiantigen Sequence Typing
We further investigated samples testing positive for 
mosaicPBP2 by using N. gonorrhoeae multiantigen se-
quence typing (NG-MAST) (19) as described previously 
(20). NG-MAST involves DNA sequencing of 2 variable 
gonococcal genes and therefore provides greater discrimi-
nation than MLST.
Australian Gonococcal Surveillance Program Data
The Australian Gonococcal Surveillance Program receives 
and tests clinical isolates of gonococci for the purposes of 
AMR phenotypic surveillance from throughout Australia. 
In 2014, the program received 222 isolates from the North-
ern Territory for antimicrobial drug susceptibility testing 
(Table 2). We compared the phenotypic rates of resistance 
with the results of PCR testing for the Northern Territory as 
a whole and individually by CAZ and ZAP regions.
Results
Of the 1,629 samples, 18.8% to 31.2% could not be charac-
terized by the PCR methods (Table 1). However, these values 
excluded the mosaicPBP2-PCR and A8806-PCR methods; 
we considered all negative results for the mosaicPBP2-PCR 
and A8806-PCR characterized because pooled samples were 
used for screening, and it was therefore not possible to as-
certain characterization for individual samples. Compared 
with culture, which provided 81 isolates from CAZ areas and 
141 from ZAP regions in this year (Table 2), the PCR as-
says (based on the average number of characterized samples 
by each PCR) provided 4.2 times more data (mean 338.6 
samples) from CAZ regions and 9.4 times more data 
(mean 1,331.6 samples) from ZAP regions.
We compared characterization rates based on ana-
tomic site and originating laboratory (online Technical 
Appendix Table); only the GyrA91-PCR results were 
used for this comparison. We observed a significantly 
lower (p<0.001) characterization rate for pharyngeal 
samples (26.7%) compared with the combined rate 
(76.7%, range 56.7%–100%) for all other sample types.
N. gonorrhoeae Resistance
We compared PCR (Table 1) and culture (Table 2) data 
for resistance to azithromycin, ceftriaxone, ciprofloxacin, 
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and penicillin. The combined results of the 2611-PCR and 
2059-PCR assays showed that N. gonorrhoeae azithromy-
cin resistance was low (0.2%) across the Northern Territory 
in 2014, consistent with the 2014 culture-based data that 
showed no azithromycin-resistant isolates. We found 10 
(0.6%) samples positive by the mosaicPBP2-PCR, all in CAZ 
regions; these data were consistent with 3 (1.4%) isolates 
exhibiting decreased susceptibility to ceftriaxone in CAZ 
regions detected by culture. We observed no A8806-PCR 
positive samples, consistent with culture data showing no 
N. gonorrhoeae with MICs for ceftriaxone >0.125 mg/L 
isolated in the Northern Territory or elsewhere in Australia 
since the A8806 strain was observed in late 2013. 
Total ciprofloxacin resistance in the Northern Territo-
ry was significantly lower by PCR (5.8%) than by bacterial 
culture (12.6%; p<0.001). Consistent with the culture data, 
the GyrA91-PCR indicated that levels of ciprofloxacin re-
sistance were higher in the CAZ region compared with the 
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Table 1. PCR results for the 1,629 NAAT-positive Neisseria gonorrhoeae clinical samples taken from patients in the Northern Territory 
of Australia, 2014* 
Assay and targets 
Results 
CAZ region, n = 441 
 
ZAP region, n = 1,188 
 
Total for both regions, n = 1,629 
No. samples/ 
no. tested 
% Samples  
(95% CI) 
No. samples/ 
no. tested 
% Samples  
(95% CI) 
No. samples/ 
no. tested 
% Samples  
(95% CI) 
GyrA91-PCR (gyrA)         
 Wild type (S91) 235/297 79.1 (74.1–83.4)  922/931 99.0 (98.2–99.5)  1,157/1,228 94.2 (92.8–95.4) 
 S91F 62/297 20.9 (16.6–25.9)  9/931 1.0 (0.5–1.8)  71/1,228 5.8 (4.6–7.2) 
 Uncharacterized† 144 32.6  257 21.6  401/1,629 24.6 
PPNG-PCR         
 Negative 252/286 88.1 (83.8–91.4)  879/888 99 (98.1–99.5)  1,131/1,174 96.3 (95.1–97.3) 
 PPNG 34/286 11.9 (8.6–16.2)  9/888 1 (0.5–1.9)  43/1,174 3.7 (2.7–4.9) 
 Uncharacterized† 155 35.1  300 25.3  455/1,629 27.9 
2611-PCR (23S rRNA)        
 Wild type 321/321 100 (98.8–100)  958/960 99.8 (99.2–99.9)  1,279/1,281 99.8 (99.4–100) 
 C2611T 0/321 0 (0–1.2)  2/960 0.2 (0.1–0.8)  2/1,281 0.2 (0–0.6) 
 Uncharacterized† 120 27.2  228 19.2  348/1,629 21.4 
2059-PCR (23S rRNA)        
 Wild type 319/319 100 (98.8–100)  1,004/1,004 100 (99.6–100)  1,323/1,323 100 (99.7–100) 
 A2059G 0/319 0 (0–1.2)  0/1,004 0 (0–0.4)  0/1,323 0 (0–0.3) 
 Uncharacterized† 122 27.7  184 15.5  306/1,629 18.8 
PorB-PCR (porB)         
 G101/A102 98/286 34.3 (29–39.9)  125/835 15.0 (12.7–17.6)  223/1,121 19.9 (17.7–22.3) 
 [G101/A102,  
 non-PPNG]‡  
[80/280]  [28.6 (23.4–34.1)]  [116/823]  [14.1 (11.9–16.6)]  [196/1,103]  [17.8 (15.6–20.1)] 
 PorB1a  152/286  53.1 (47.4–58.9)  699/835  83.7 (81.1–86.1)  851/1,121  75.9 (73.3–78.3) 
 [PorB1a,  
 non-PPNG]‡ 
 [120/267]  [44.9 (39.1–50.9)]   [627/770]  [81.3 (78.4–83.9)]   [747/1,037]  [72.0 (69.2–74.7)] 
 Mutant§ 32/286 11.2 (8–15.4)  3/835 0.4 (0.1–1.1)  35/1,121 3.1 (2.3–4.3) 
 PorB1a and  
 G101/A102 
4/286 1.4 (0.5–3.5)  6/835 0.7 (0.3–1.6)  10/1,121 0.9 (0.5–1.6) 
 PorB1a and  
 mutant§ 
0/286 0 (0–1.3)  2/835 0.2 (0.1–0.9)  2/1,121 0.2 (0–0.6) 
 Uncharacterized† 155 35.1  353 29.8  508/1,629 31.2 
A-deletion-PCR (MtrR)        
 Wild type  280/318  88.1 (84–91.2)  944/950  99.4 (98.6–99.7)  1,224/1,268  96.5 (95.4–97.4) 
 [Wild type,  
 non-PPNG]‡ 
[226/284] [79.6 (74.5–84.1)]  [861/873] [98.6 (97.6–99.2)]  [1,087/1,157] [93.9 (92.4–95.2)] 
 A-deletion 38/318 11.9 (8.8–16)  6/950 0.6 (0.3–1.4)  44/1268 3.5 (2.6–4.6) 
 Uncharacterized† 123 27.9  238 20  361/1629 22.2 
mosaicPBP2-PCR (penA)        
 Negative 431/441 97.7 (95.9–98.8)  1,188/1,188 100 (99.7–100)  1,619/1,629 99.4 (98.9–99.7) 
 Positive 10/441 2.3 (1.2–4.1)  0/1188 0 (0–0.3)  10/1,629 0.6 (0.3–1.1) 
 Uncharacterized†¶ NA NA  NA NA  NA NA 
A8806-PCR (penA)         
 Negative 441/441 100 (99.1–100)  1,188/1,188 100 (99.7–100)  1,629/1,629 100 (99.8–100) 
 Positive 0/441 0 (0–0.9)  0/1,188 0 (0–0.3)  0/1,629 0 (0–0.2) 
 Uncharacterized†¶ NA NA  NA NA  NA NA 
*NA, not applicable; NAAT, nucleic acid amplification test; PPNG, penicillinase-producing N. gonorrhoeae. 
†These samples could not be characterized by the respective PCR assay.  
‡These PorB-PCR and A-deletion-PCR results were combined with the PPNG-PCR results to exclude those that were PPNG. Uncharacterized PPNG-
PCR results were omitted from total numbers. 
§Mutant = G101K/A102D, G101K/A102N or G101K/A102G.  
¶All negative results for the mosaicPBP2-PCR and A8806-PCR were considered valid (i.e., characterized) given that pooled samples were used for 
screening, and it was therefore not possible to ascertain characterization for individual samples. 
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ZAP region. Similarly, total levels of PPNG in the North-
ern Territory as determined by PCR (3.7%) were signifi-
cantly lower than the levels determined by culture (8.1%); 
p<0.01). For ZAP regions, PPNG-PCR testing showed that 
1.0% of samples were PPNG positive, comparable to the 
2.1% observed with bacterial culture. 
Using bacterial culture, we detected no isolates with 
chromosomally mediated resistance to penicillin (CMRP) 
in ZAP regions. Although the porB-PCR is not a definitive 
marker of CMRP (17), it was still able to provide insight 
into CMRP, given that the G101/A102 and PorB1a markers 
are highly predictive of penicillin susceptibility (in which 
PPNG strains are simultaneously detected and excluded). 
In the ZAP regions, 14.1% of samples were both non-
PPNG and G101/A102 and 81.3% were both non-PPNG 
and PorB1a, providing 95.4% of samples predicted to be 
susceptible to penicillin. Thus, based on the combined 
porB-PCR and PPNG-PCR results, we predicted by PCR 
that  95.4%–99% of samples were susceptible to penicillin. 
These data are further supported by the combined A-de-
letion-PCR and PPNG-PCR data; 98.6% of samples from 
ZAP regions possessed a wild-type mtrR promoter and 
were non-PPNG.
MLST
Of the 717 samples that we subjected to iPLEX14SNP 
genotyping, 456 (63.6%) were successfully genotyped 
and 261 (36.4%) were not characterized. We excluded 
the uncharacterized samples from further analysis. We 
observed 27 different iPLEX14SNP genotypes for the 
456 characterized samples and summarized the 14 most 
common (NG01 to NG14, consisting of those with 5 or 
more isolates; total, 437 isolates), indicating whether they 
were from the CAZ or ZAP regions (Figure 2). A total 
of 10 iPLEX14SNP genotypes were shared across both 
CAZ and ZAP regions, including 8 of the 14 most com-
mon. Examination of available PCR data associated with 
these 10 genotypes shared between CAZ and ZAP regions 
revealed that 3 possessed resistance markers, including 
NG07 (GyrA S91F, mtrR A-deletion, and PorB mutant 
sequences), NG13 (GyrA S91F and PPNG), and a third 
genotype (GyrA S91F mtrR A-deletion and PPNG), listed 
among “all others” in Figure 2.
NG-MAST Investigation of mosaicPBP2-PCR  
Positive Samples
The NG-MAST analyses for the 10 samples positive 
by the mosaicPBP2-PCR (Table 3) revealed 4 different 
types, including 3 types (2212, 5622, and 1407) that have 
previously been associated with the gonococcal mosaic 
PBP2 in Europe and elsewhere (21). Additional demo-
graphic data were obtained; the 10 samples were from 7 
men and 2 women, including 3 Aboriginal (1 man and 2 
women) and 6 non-Aboriginal persons. All of these per-
sons were identified in the metropolitan area of Darwin in 
the Northern Territory.
Discussion
The results of this study show conclusively that molecular 
methods can be used to enhance N. gonorrhoeae AMR 
surveillance for a range of antimicrobial drugs in an iso-
lated region where bacterial culture is impractical or not 
possible. For the Northern Territory of Australia, these 
new data substantially increase the evidence base for the 
current treatment guidelines, characterizing approximate-
ly two thirds of all notified cases, compared with only 
13% (222/1740) that were available for characterization 
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Table 2. Summary of the Australian Gonococcal Surveillance Program culture-based Neisseria gonorrhoeae antimicrobial drug 
resistance data for the Northern Territory of Australia, 2014* 
Antimicrobial drug 
CAZ region, n = 81 
 
ZAP region, n = 141 
 
Total, n = 222 
No. isolates % Isolates (95% CI) No. isolates % Isolates (95% CI) No. isolates % Isolates (95% CI) 
Azithromycin R 0 0.0 (0.0–4.5)  0 0.0 (0.0–2.7)  0 0.0 (0.0–1.7) 
Ceftriaxone DS 3 3.7 (1.3–10.3)  0 0.0 (0.0–2.7)  3 1.4 (0.5–3.9) 
Ciprofloxacin R 25 30.9 (21.9–41.6)  3 2.1 (0.7–6.1)  28 12.6 (8.9–17.6) 
Penicillin R 21 25.9 (17.6–36.4)  3  2.1 (0.7–6.1)  24 10.8 (7.4–15.6) 
 PPNG 15 18.5 (11.6–28.3)  3 2.1 (0.7–6.1)  18 8.1 (5.2–12.5) 
*Adapted from the Australian Gonococcal Surveillance Program annual report) (10). DS, decreased susceptibility; PPNG, penicillinase-producing N. 
gonorrhoeae; R, resistant.  
 
Figure 2. Genotype frequency of the 456 Neisseria gonorrhoeae 
clinical samples taken from patients in the Northern Territory of 
Australia, 2014, that were successfully genotyped by using the 
iPLEX14SNP method (9). Presence of each genotype in the  
CAZ or ZAP regions is indicated. CAZ, ceftriaxone via 
intramuscular injection and oral azithromycin; ZAP, azithromycin, 
amoxicillin, probenecid.
 Resistance Surveillance for N. gonorrhoeae
by culture. Furthermore, the data indicate no ceftriaxone 
resistance and little azithromycin resistance (0.2%) in this 
region and provide an estimate that penicillin resistance is 
<5% in the ZAP regions.
This case study also highlights the potential for mo-
lecular assays to inform alternative treatment strategies in 
areas where culture-based testing may be limited. The high 
ciprofloxacin susceptibility levels indicate that ciprofloxa-
cin would be suitable as an alternative oral therapy in the 
ZAP regions; the GyrA91-PCR showed that 99.0% of in-
fections in the ZAP regions were ciprofloxacin susceptible. 
Thus, ciprofloxacin could be used empirically or could 
otherwise be of value where use of the ZAP pack is con-
traindicated (e.g., penicillin allergy) or to facilitate patient-
delivered partner therapy (PDPT). Although PDPT for 
chlamydia is supported in the Northern Territory, it is not 
recommended for gonorrhea given the risk of anaphylaxis 
with penicillin and the injection requirement for ceftriax-
one. Based on our data, ciprofloxacin could appropriately 
be used for PDPT for gonorrhea in the ZAP regions, ideally 
in combination with azithromycin to simultaneously treat 
both chlamydia and gonorrhea given the high coinfection 
rates in these areas (22). 
A further benefit of using ciprofloxacin in ZAP regions 
is that rates of susceptibility/resistance could be monitored 
accurately by molecular methods, such as the GyrA91-
PCR. This assay could also facilitate use of oral ciprofloxa-
cin in the CAZ regions through individualized treatment, 
which, based on the prevalence of wild-type (susceptible) 
strains, could be used for 79.1% of patients, substantially 
sparing the use of ceftriaxone. Similarly, based on the com-
bined results of the PorB-PCR and PPNG-PCR methods, 
individualized ZAP pack treatment could potentially be 
used for 73.5% of infections in the CAZ regions.
The data also provide some evidence of new threats to 
current treatments. Although there was no further evidence 
of the A8806 ceftriaxone-resistant strain, the detection of 
mosaic PBP2 strains in the Northern Territory, particularly 
among Aboriginal patients, is alarming. These mosaicPBP2 
strains typically exhibit CMRP and therefore pose a direct 
risk to the use of ZAP packs. This risk is heightened by the 
ability of these mosaicPBP2 strains to spread rapidly. First 
reported in Japan in 2001, mosaicPBP2 strains have since 
become an internationally successful clone. Accordingly, 
our nationwide study of gonococcal isolates from Australia 
in 2012 showed that mosaic strains composed 8.9% of all 
isolates and had spread to every state in Australia except 
the Northern Territory (23). The NG-MAST data from this 
study (Table 3) indicated that different incursions of the 
mosaicPBP2 strains into the Northern Territory popula-
tion occurred in 2014. It is likely that 3 of these involved 
men who have sex with men, residing in the metropolitan 
area of Darwin. The presence of the same NG-MAST type 
(2212; Table 3) in 1 Aboriginal man and 2 Aboriginal 
women strongly suggests transmission within heterosexual 
Aboriginal networks in the Darwin region.
It was previously assumed that penicillin resistance 
has remained low in ZAP regions because of limited bridg-
ing of sexual networks in metropolitan areas. This hy-
pothesis was not supported by our MLST data, however, 
which showed that 10 of the 27 observed gonococcal strain 
types (including 8 of the 14 most common strain types; 
Figure 2) were present in both CAZ and ZAP regions. 
These strains included 3 strain types predicted to be resis-
tant to ciprofloxacin, penicillin, or both, suggesting com-
mon sexual networks. Thus, it is theoretically possible that 
mosaicPBP2 strains or other resistant strains could exploit 
this bridging and spread into ZAP regions.
The addition of molecular strategies in the remote re-
gions provided a notable increase in the scope of AMR sur-
veillance. With the increased surveillance capture, the rates 
of both ciprofloxacin resistance and PPNG predicted by 
PCR were much lower (less than half) than rates detected 
by bacterial culture. In total, 9 times more samples from 
the ZAP regions were ascertained by PCR than by bacterial 
culture, compared with 4 times more samples from CAZ 
regions ascertained by PCR than by culture. Previous Aus-
tralia data have shown that the GyrA91-PCR assay is an ac-
curate predictor of ciprofloxacin resistance and the PPNG-
PCR assay is an accurate predictor of PPNG (11,14,15). 
Therefore, it is unlikely that the observed differences 
between PCR and culture-based data were attributable 
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Table 3. Summary of mosaicPBP2-PCR–positive Neisseria gonorrhoeae samples from the Northern Territory of Australia* 
Patient no. Sex Age group, y Aborigine Sample source Date of collection NG-MAST genotype 
1 M 51–55 No Urine January 2014 10038 
2 M 21–25 No Urine March 2014 2212 
3 F 26–30 Yes Urine April 2014 2212 
Pharyngeal swab May 2014 2212 
4 M 26–30 Yes Urine April 2014 2212 
5 F <20 Yes Urine May 2014 2212 
6 M 21–25 No Urine February 2014 5622 
7 M 56–60 No Urine December 2014 5622 
8 M 21–25 No Anal swab November 2014 1407 
9 M 21–25 No Anal swab November 2014 1407 
*NG-MAST, N. gonorrhoeae multiantigen sequence typing. 
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to problems with accuracy of the PCR target sequences. 
Rather, we suspect that the observed differences in resis-
tance rates were influenced primarily by the higher propor-
tion of infections that were able to be characterized in the 
ZAP region with these PCR assays. Our findings strongly 
support the CDC’s and WHO’s positions on the utility of 
molecular strategies to enhance surveillance (1,2). Rates 
of drug resistance are rising, and refining and rationalizing 
antimicrobial drug use at the individual patient level is a 
desirable stewardship strategy.
Our study has several limitations. The predictive value 
of the molecular markers used in this study are based on 
Australia sample banks, so they may not be representative 
of other regions, where different gonococcal strains may be 
circulating. This limitation is particularly relevant for the 
PorB-PCR PIA target, which, as previously described, does 
not specifically target a mechanism of resistance, yet is high-
ly associated with penicillin susceptibility in local Australia 
gonococci (17). These issues highlight the importance of 
maintaining culture-based AMR testing for definitive AMR 
surveillance, as well as for providing ongoing validation ma-
terial for the molecular methods. In addition, we observed 
that approximately one third of N. gonorrhoeae NAAT-posi-
tive clinical samples could not be characterized by 1 or more 
of the resistance assays; this finding is likely due to low DNA 
loads, as previously documented (16). The lack of charac-
terization was particularly evident for pharyngeal samples, 
which likely reflects N. gonorrhoeae DNA loads being gen-
erally lower in the pharynx compared with other sites.
Overall, this study highlights the potential for mo-
lecular methods to enhance culture-based AMR sur-
veillance programs by increasing sample size. These 
methods have provided, and continue to provide, new 
representative data to inform local treatment guidelines, 
identifying alternative treatment options and pinpoint-
ing new resistance threats. Molecular methods, such as 
those described here, offer new opportunities to improve 
N. gonorrhoeae AMR surveillance globally, particularly 
in remote regions.
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